- Home
- TURN vs AKTX Comparison
TURN vs AKTX Comparison
Compare TURN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- AKTX
- Stock Information
- Founded
- TURN 1981
- AKTX N/A
- Country
- TURN United States
- AKTX United States
- Employees
- TURN N/A
- AKTX N/A
- Industry
- TURN Finance/Investors Services
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TURN Finance
- AKTX Health Care
- Exchange
- TURN Nasdaq
- AKTX Nasdaq
- Market Cap
- TURN 39.9M
- AKTX 37.2M
- IPO Year
- TURN N/A
- AKTX N/A
- Fundamental
- Price
- TURN $4.11
- AKTX $1.14
- Analyst Decision
- TURN
- AKTX
- Analyst Count
- TURN 0
- AKTX 0
- Target Price
- TURN N/A
- AKTX N/A
- AVG Volume (30 Days)
- TURN 21.6K
- AKTX 26.9K
- Earning Date
- TURN 01-01-0001
- AKTX 08-18-2025
- Dividend Yield
- TURN N/A
- AKTX N/A
- EPS Growth
- TURN N/A
- AKTX N/A
- EPS
- TURN N/A
- AKTX N/A
- Revenue
- TURN $194,813.00
- AKTX N/A
- Revenue This Year
- TURN N/A
- AKTX N/A
- Revenue Next Year
- TURN N/A
- AKTX N/A
- P/E Ratio
- TURN N/A
- AKTX N/A
- Revenue Growth
- TURN 254.25
- AKTX N/A
- 52 Week Low
- TURN $3.12
- AKTX $0.85
- 52 Week High
- TURN $4.25
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- TURN 64.70
- AKTX 43.82
- Support Level
- TURN $3.93
- AKTX $1.10
- Resistance Level
- TURN $4.02
- AKTX $1.18
- Average True Range (ATR)
- TURN 0.07
- AKTX 0.05
- MACD
- TURN 0.01
- AKTX 0.00
- Stochastic Oscillator
- TURN 77.18
- AKTX 39.52
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.